KIT CAR T-Cells with Novel Co-Stimulatory Domain for Use Treating Solid and Liquid Tumors

SK2019-014

KIT CAR T-Cells with Novel Co-Stimulatory Domain for Use Treating Solid and Liquid Tumors

SK2019-014

Share
Print
Share
Print

SUMMARY OF INVENTION

This technology seeks to expand the efficacy of CAR T-cell immunotherapies through use of a novel co-stimulatory domain that replaces the more commonly used 41BB or CD28.  MSK investigators have developed CARs that encode a KIT domain in the cytoplasmic signaling pathway, which confers the CAR T-cell with improved proliferation and better cytotoxicity against low-antigen-expressing targets. This improved co-stimulatory domain can be part of any CAR T-cell, and it is believed that KIT CARs could be used in immunotherapies for many different types of solid and liquid tumors.

The KIT domain includes a mutation which has been shown to limit apoptosis and promote proliferation in mast cells. It is unique for a number of reasons, including that oncogenicity is established only in the presence of other mutations; it can signal without ligand/receptor interaction; and it is independent of SHP1/2 inhibition, and therefore has the potential to avoid PD-L1/2-PD-1 inhibition. Preliminary data indicates that KIT CARs proliferate only in the presence of antigen stimulation and that they are sensitive to switch pocket inhibitors already in clinical use to treat mast cell syndrome and KIT mutant cancers.

ADVANTAGE

  • Platform technology, with potential to significantly expand use of CAR T immunotherapies to those patients with solid and liquid tumors
  • Compares favorably to current CARs, with improved proliferation and stronger cytotoxicity against low-antigen-expressing targets
  • Ability to address unexpected cytotoxicity issues with “safety switches” already in clinical use

 
MARKET OPPORTUNITIES
Once commercialized, CAR T-cell therapies are expected to provide treatment for millions of cancer patients, with market size projected to reach $8.5B by 2028. While the initial product will be a mesothelin-targeted KIT CAR treating patients suffering from non-small-cell lung cancer, it is anticipated that KIT CARs could be used in many different types of CAR T-cell immunotherapies for solid and liquid tumors.
 
STAGE OF DEVELOPMENT
Preclinical


PATENT INFORMATION
Provisional application 62/943,032 filed Dec. 3, 2019
 
LEAD INVESTIGATOR Prasad Adusumilli, MD, Deputy Chief, Thoracic Service, Memorial Sloan Kettering
 
CONTACT INFORMATION
Eileen Flowers, PhD
Senior Manager, Business Development & Licensing
Tel: 646-888-1067
E-mail: flowerse@mskcc.org

Stage of Development

In vitro